Disclosure · Form 10-K · fiscal 2025
Oncotelic Therapeutics, Inc. 10-K cybersecurity disclosure (Item 1C), fiscal 2025
Filed April 15, 2026· period ended December 31, 2025· OTLC· CIK 908259· Updated · filing on sec.gov ↗
Oncotelic Therapeutics, Inc.'s Form 10-K for fiscal 2025, filed April 15, 2026, places oversight of cybersecurity risk with the full board; a top security role title is not identified.
What Oncotelic Therapeutics' Item 1C says
Oncotelic Therapeutics' Form 10-K for fiscal 2025 places oversight of cybersecurity risk with the full Board of Directors. The filing says the CEO plays a role in informing the Board of Directors on cybersecurity risks.
Board and management oversight
The full Board of Directors is responsible for oversight of cybersecurity risks because the company has no functional Audit Committee at this time. The CEO briefs the Audit Committee on a regular basis, with a minimum frequency of once per year. The Board plans to establish oversight mechanisms for governance in managing risks associated with cybersecurity threats.
How the company manages cyber risk
The company has integrated cybersecurity risk management into its broader risk management framework. The risk management team works to continuously evaluate and address cybersecurity risks in alignment with business objectives and operational needs.
Third parties and incidents
The company plans to engage external experts, including cybersecurity assessors and auditors, in evaluating and testing its risk management systems. Because the company is aware of risks associated with third-party service providers, it plans to implement processes to oversee and manage these risks. The company plans to conduct security assessments of all third-party providers before engagement and to maintain ongoing monitoring for compliance with its cybersecurity standards. The filing states that the monitoring will include periodic assessments by the company's Chief Executive Officer. The company states it has not encountered cybersecurity challenges that have materially impaired its operations or financial standing.
What the section does not state
The section does not name the person who holds the top security role. The section does not name a specific security framework or standard.
Read from the Form 10-K filed April 15, 2026, on . Every sentence rests on a passage of the section reproduced below.
The filing's fields, each with its sentence
Who leads security (the top role, as the filing names it)
not identified
Reports to
not identified
Board oversight
Full board
“In the absence of a functional Audit Committee at this time, the full Board of Directors is responsible to oversight the cybersecurity risks for the Company.”
CISO or other person named
not identified
Frameworks and standards named
not identified
Outside assessors, consultants or testers
not identified
Experience of the security leadership, as stated
not identified
Material incident
The filing states none
“We have no t encountered cybersecurity challenges that have materially impaired our operations or financial standing.”
The section
457 words, Form 10-K filed April 15, 2026 for the period ended December 31, 2025
Read by claude-sonnet-5-5 on November 12, 2026; every quote verified in the stored text by code.
How peers in the same industry describe the seat
The SEC assigns Oncotelic Therapeutics, Inc. standard industrial classification 2834, Pharmaceutical preparations (SEC SIC list). 8 other filers in our library have the same code.
| Filer | Top security role | Reports to | Board oversight |
|---|---|---|---|
| Nanoviricides, Inc.FY 2026, filed September 28, 2026 | not identified | not identified | audit committee |
| Phibro Animal Health CorpFY 2026, filed August 26, 2026 | Chief Technology and Digital Innovation Officer | not identified | full board |
| Protagenic Therapeutics, Inc.\newFY 2026, filed August 14, 2026 | not identified | not identified | audit committee |
| Earth Science Tech, Inc.FY 2026, filed June 18, 2026 | not identified | not identified | not identified |
| GeoVax Labs, Inc.FY 2025, filed April 15, 2026 | Chief Financial Officer | not identified | Nominating and Governance Committee |
| KALA BIO, Inc.FY 2025, filed April 15, 2026 | Chief Business Officer | not identified | Audit Committee |
| Sunshine Biopharma Inc.FY 2025, filed April 3, 2026 | not identified | not identified | not identified |
| LFTD Partners Inc.FY 2025, filed April 1, 2026 | not identified | not identified | not identified |
Item 1C, verbatim from the filing
The text below is the Cybersecurity item of Oncotelic Therapeutics, Inc.'s Form 10-K as filed with the SEC on April 15, 2026, reproduced word for word from the filing on sec.gov. Page numbers and navigation lines have been removed; nothing has been added. It describes governance as of that date.
ITEM
1C. CYBERSECURITY RISK MANAGEMENT, STRATEGY, AND GOVERNANCE.
Risk
management and strategy
The
Company recognizes the critical importance of developing, implementing, and maintaining robust cybersecurity measures to safeguard our
information systems and protect the confidentiality, integrity, and availability of our data.
Managing
Material Risks & Integrated Overall Risk Management
The
Company has strategically integrated cybersecurity risk management into our broader risk management framework to promote a company-wide
culture of cybersecurity risk management. This integration ensures that cybersecurity considerations are an integral part of our decision-making
processes at every level. Our risk management team works to continuously evaluate and address cybersecurity risks in alignment with our
business objectives and operational needs.
Engage
Third-parties on Risk Management, as required
Recognizing
the complexity and evolving nature of cybersecurity threats, the Company plans to engage external experts, including cybersecurity assessors
and auditors in evaluating and testing our risk management systems. These partnerships would enable us to leverage specialized knowledge
and insights, ensuring our cybersecurity strategies and processes remain at the forefront of industry best practices. Our possible collaborations
with these third-parties will include regular audits, threat assessments, and consultation on security enhancements.
Oversee
Third-party Risk
Because
we are aware of the risks associated with third-party service providers, the Company plans to implement processes to oversee and manage
these risks. We plan to conduct thorough security assessments of all third-party providers before engagement and maintain ongoing monitoring
to ensure compliance with our cybersecurity standards. The monitoring will include periodic assessments by our Chief Executive Officer
("CEO"). This approach will be planned to design to mitigate risks related to data breaches or other security incidents originating
from third-parties.
Risks
from Cybersecurity Threats
We
have no t encountered cybersecurity challenges that have materially impaired our operations or financial standing.
Governance
The
Board of Directors is acutely aware of the critical nature of managing risks associated with cybersecurity threats. The Board plans to
establish robust oversight mechanisms to ensure effective governance in managing risks associated with cybersecurity threats because
we recognize the significance of these threats to our operational integrity and stakeholder confidence,
Board
of Directors Oversight
In
the absence of a functional Audit Committee at this time, the full Board of Directors is responsible to oversight the cybersecurity risks
for the Company.
Management's
Role Managing Risk
The
CEO plays a pivotal role in informing the Board of Directors on cybersecurity risks. The CEO provides comprehensive briefings to the
Audit Committee on a regular basis, with a minimum frequency of once per year. These briefings encompass a broad range of topics, including:
●
Current
cybersecurity landscape and emerging threats;
●
Status
of ongoing cybersecurity initiatives and strategies;
●
Incident
reports and learnings from any cybersecurity events; and
●
Compliance
with regulatory requirements and industry standards.
The fields above are exact quotes from the stored text. "Not identified" means no supporting sentence was found, not that the company has no such arrangement. A name in a filing is not a record of who holds the seat today: the Wire tracks that.
Browse the whole library at /disclosures, or see who the top security role reports to, by sector. Cite as "CISO Tribune, 10-K cybersecurity governance disclosures" with a link.